|
1
|
Hide T, Komohara Y, Miyasato Y, Nakamura
H, Makino K, Takeya M, Kuratsu JI, Mukasa A and Yano S:
Oligodendrocyte progenitor cells and macrophages/microglia produce
glioma stem cell niches at the tumor border. EBioMedicine.
30:94–104. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Troike KM, Acanda de la Rocha AM, Alban
TJ, Grabowski MM, Otvos B, Cioffi G, Waite KA, Barnholtz Sloan JS,
Lathia JD, Guilarte TR and Azzam DJ: The Translocator Protein
(TSPO) genetic polymorphism A147T is associated with worse survival
in male glioblastoma patients. Cancers (Basel). 13:45252021.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lara-Velazquez M, Al-Kharboosh R,
Jeanneret S, Vazquez-Ramos C, Mahato D, Tavanaiepour D, Rahmathulla
G and Quinones-Hinojosa A: Advances in brain tumor surgery for
glioblastoma in adults. Brain Sci. 7:1662017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
De Barros A, Attal J, Roques M, Nicolau J,
Sol JC, Cohen-Jonathan-Moyal E and Roux FE: Impact on survival of
early tumor growth between surgery and radiotherapy in patients
with de novo glioblastoma. J Neurooncol. 142:489–497. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Karachi A, Dastmalchi F, Mitchell DA and
Rahman M: Temozolomide for immunomodulation in the treatment of
glioblastoma. Neuro Oncol. 20:1566–1572. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gujar AD, Le S, Mao DD, Dadey DY, Turski
A, Sasaki Y, Aum D, Luo J, Dahiya S, Yuan L, et al: An NAD +
-dependent transcriptional program governs self-renewal and
radiation resistance in glioblastoma. Proc Natl Acad Sci USA.
113:E8247–E8256. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Perazzoli G, Prados J, Ortiz R, Caba O,
Cabeza L, Berdasco M, Gónzalez B and Melguizo C: Temozolomide
resistance in glioblastoma cell lines: Implication of MGMT, MMR,
P-glycoprotein and CD133 expression. PLoS One. 10:e01401312015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Colwell N, Larion M, Giles AJ, Seldomridge
AN, Sizdahkhani S, Gilbert MR and Park DM: Hypoxia in the
glioblastoma microenvironment: Shaping the phenotype of cancer
stem-like cells. Neuro Oncol. 19:887–896. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sun H, Zhang M, Cheng K, Li P, Han S, Li
R, Su M, Zeng W, Liu J, Guo J, et al: Resistance of glioma cells to
nutrient-deprived microenvironment can be enhanced by
CD133-mediated autophagy. Oncotarget. 7:76238–76249. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lathia JD, Mack SC, Mulkearns-Hubert EE,
Valentim CLL and Rich JN: Cancer stem cells in glioblastoma. Genes
Dev. 29:1203–1217. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Blake PW and Toro JR: Update of
cylindromatosis gene (CYLD) mutations in Brooke-Spiegler syndrome:
Novel insights into the role of deubiquitination in cell signaling.
Hum Mutat. 30:1025–1036. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sun SC: CYLD: A tumor suppressor
deubiquitinase regulating NF-kappaB activation and diverse
biological processes. Cell Death Differ. 17:25–34. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Urbanik T, Köhler BC, Boger RJ, Wörns MA,
Heeger S, Otto G, Hövelmeyer N, Galle PR, Schuchmann M, Waisman A
and Schulze-Bergkamen H: Down-regulation of CYLD as a trigger for
NF-κB activation and a mechanism of apoptotic resistance in
hepatocellular carcinoma cells. Int J Oncol. 38:121–131.
2011.PubMed/NCBI
|
|
15
|
Lim JH, Jono H, Komatsu K, Woo CH, Lee J,
Miyata M, Matsuno T, Xu X, Huang Y, Zhang W, et al: CYLD negatively
regulates transforming growth factor-β-signalling via
deubiquitinating Akt. Nat Commun. 3:7712012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shinriki S, Jono H, Maeshiro M, Nakamura
T, Guo J, Li JD, Ueda M, Yoshida R, Shinohara M, Nakayama H, et al:
Loss of CYLD promotes cell invasion via ALK5 stabilization in oral
squamous cell carcinoma. J Pathol. 244:367–379. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Reiley W, Zhang M and Sun SC: Negative
regulation of JNK signaling by the tumor suppressor CYLD. J Biol
Chem. 279:55161–55167. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tesio M, Tang Y, Müdder K, Saini M, von
Paleske L, Macintyre E, Pasparakis M, Waisman A and Trumpp A:
Hematopoietic stem cell quiescence and function are controlled by
the CYLD-TRAF2-p38MAPK pathway. J Exp Med. 212:525–538. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jono H, Lim JH, Chen LF, Xu H, Trompouki
E, Pan ZK, Mosialos G and Li JD: NF-κB is essential for induction
of CYLD, the negative regulator of NF-κB. J Biol Chem.
279:36171–36174. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yoshida H, Jono H, Kai H and Li JD: The
Tumor suppressor cylindromatosis (CYLD) acts as a negative
regulator for Toll-like Receptor 2 signaling via negative
Cross-talk with TRAF6 and TRAF7. J Biol Chem. 280:41111–41121.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sakai A, Koga T, Lim JH, Jono H, Harada K,
Szymanski E, Xu H, Kai H and Li JD: The bacterium, nontypeable
Haemophilus influenzae, enhances host antiviral response by
inducing Toll-like receptor 7 expression: Evidence for negative
regulation of host anti-viral response by CYLD. FEBS J.
274:3655–3668. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lim JH, Stirling B, Derry J, Koga T, Jono
H, Woo CH, Xu H, Bourne P, Ha UH, Ishinaga H, et al: Tumor
Suppressor CYLD regulates acute lung injury in lethal streptococcus
pneumoniae infections. Immunity. 27:349–360. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lim JH, Jono H, Koga T, Woo CH, Ishinaga
H, Bourne P, Xu H, Ha UH, Xu H and Li JD: Tumor suppressor CYLD
acts as a negative regulator for non-typeable haemophilus
influenza-induced inflammation in the middle ear and lung of mice.
PLoS One. 2:e10322007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Koga T, Lim JH, Jono H, Ha UH, Xu H,
Ishinaga H, Morino S, Xu X, Yan C, Kai H and Li JD: Tumor
suppressor cylindromatosis acts as a negative regulator for
streptococcus pneumoniae-induced NFAT signaling. J Biol Chem.
283:12546–12554. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Komatsu K, Lee JY, Miyata M, Hyang Lim J,
Jono H, Koga T, Xu H, Yan C, Kai H and Li JD: Inhibition of PDE4B
suppresses inflammation by increasing expression of the
deubiquitinase CYLD. Nat Commun. 4:16842013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Harsha HC and Pandey A: Phosphoproteomics
in cancer. Mol Oncol. 4:482–495. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Massoumi R, Kuphal S, Hellerbrand C, Haas
B, Wild P, Spruss T, Pfeifer A, Fässler R and Bosserhoff AK:
Down-regulation of CYLD expression by Snail promotes tumor
progression in malignant melanoma. J Exp Med. 206:221–232. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Suenaga N, Kuramitsu M, Komure K, Kanemaru
A, Takano K, Ozeki K, Nishimura Y, Yoshida R, Nakayama H, Shinriki
S, et al: Loss of tumor suppressor CYLD expression triggers
cisplatin resistance in oral squamous cell carcinoma. Int J Mol
Sci. 20:51942019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hayashi M, Jono H, Shinriki S, Nakamura T,
Guo J, Sueta A, Tomiguchi M, Fujiwara S, Yamamoto-Ibusuki M,
Murakami K, et al: Clinical significance of CYLD downregulation in
breast cancer. Breast Cancer Res Treat. 143:447–457. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guo J, Shinriki S, Su Y, Nakamura T,
Hayashi M, Tsuda Y, Murakami Y, Tasaki M, Hide T, Takezaki T, et
al: Hypoxia suppresses cylindromatosis (CYLD) expression to promote
inflammation in glioblastoma: Possible link to acquired resistance
to anti-VEGF therapy. Oncotarget. 5:6353–6364. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zemke NR, Gou D and Berk AJ:
Dedifferentiation by adenovirus E1A due to inactivation of Hippo
pathway effectors YAP and TAZ. Genes Dev. 33:828–843. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Trompouki E, Hatzivassiliou E, Tsichritzis
T, Farmer H, Ashworth A and Mosialos G: CYLD is a deubiquitinating
enzyme that negatively regulates NF-kappaB activation by TNFR
family members. Nature. 424:793–796. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Balenci L, Clarke ID, Dirks PB, Assard N,
Ducray F, Jouvet A, Belin MF, Honnorat J and Baudier J: IQGAP1
protein specifies amplifying cancer cells in glioblastoma
multiforme. Cancer Res. 66:9074–9082. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Singh SK, Hawkins C, Clarke ID, Squire JA,
Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Puchalski RB, Shah N, Miller J, Dalley R,
Nomura SR, Yoon JG, Smith KA, Lankerovich M, Bertagnolli D, Bickley
K, et al: An anatomic transcriptional atlas of human glioblastoma.
Science. 360:660–663. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Masuda T, Saito N, Tomita M and Ishihama
Y: Unbiased quantitation of Escherichia coli membrane proteome
using phase transfer surfactants. Mol Cell Proteomics. 8:2770–2777.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Masuda T, Tomita M and Ishihama Y: Phase
transfer surfactant-aided trypsin digestion for membrane proteome
analysis. J Proteome Res. 7:731–740. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rappsilber J, Mann M and Ishihama Y:
Protocol for micro-purification, enrichment, pre-fractionation and
storage of peptides for proteomics using StageTips. Nat Protoc.
2:1896–1906. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rappsilber J, Ishihama Y and Mann M: Stop
and go extraction tips for matrix-assisted laser
desorption/ionization, nanoelectrospray, and LC/MS sample
pretreatment in proteomics. Anal Chem. 75:663–670. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sugiyama N, Masuda T, Shinoda K, Nakamura
A, Tomita M and Ishihama Y: Phosphopeptide enrichment by aliphatic
hydroxy acid-modified metal oxide chromatography for nano-LC-MS/MS
in proteomics applications. Mol Cell Proteomics. 6:1103–1109. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shirakawa Y, Hide T, Yamaoka M, Ito Y, Ito
N, Ohta K, Shinojima N, Mukasa A, Saito H and Jono H: Ribosomal
protein S6 promotes stem-like characters in glioma cells. Cancer
Sci. 111:2041–2051. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Miyake S, Miwa T, Yoneda G, Kanemaru A,
Saito H, Minoda R, Orita Y, Saito H and Jono H: Relationship
between clinicopathological characteristics and CYLD expression in
patients with cholesteatoma. PLoS One. 15:e02402162020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Miyake S, Kanemaru A, Saito H and Jono H:
CYLD: A novel stratification marker for malignant tumors. J Asian
Assoc Sch Pharm. 10:17–22. 2021.
|
|
44
|
Kanemaru A, Shinriki S, Kai M, Tsurekawa
K, Ozeki K, Uchino S, Suenaga N, Yonemaru K, Miyake S, Masuda T, et
al: Potential use of EGFR-targeted molecular therapies for tumor
suppressor CYLD-negative and poor prognosis oral squamous cell
carcinoma with chemoresistance. Cancer Cell Int. 22:3582022.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zuccarini M, Giuliani P, Ziberi S,
Carluccio M, Iorio PD, Caciagli F and Ciccarelli R: The role of wnt
signal in glioblastoma development and progression: A possible new
pharmacological target for the therapy of this tumor. Genes
(Basel). 9:1052018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yun EJ, Kim S, Hsieh JT and Baek ST:
Wnt/β-catenin signaling pathway induces autophagy-mediated
temozolomide-resistance in human glioblastoma. Cell Death Dis.
11:7712020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Boso D, Rampazzo E, Zanon C, Bresolin S,
Maule F, Porcù E, Cani A, Della Puppa A, Trentin L, Basso G and
Persano L: HIF-1α/Wnt signaling-dependent control of gene
transcription regulates neuronal differentiation of glioblastoma
stem cells. Theranostics. 9:4860–4877. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhu H, Chen Z, Shen L, Tang T, Yang M and
Zheng X: Long Noncoding RNA LINC-PINT suppresses cell
proliferation, invasion, and EMT by Blocking Wnt/β-Catenin
signaling in glioblastoma. Front Pharmacol. 11:5866532021.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Song L, Lin C, Gong H, Wang C, Liu L, Wu
J, Tao S, Hu B, Cheng SY, Li M and Li J: miR-486 sustains NF-κB
activity by disrupting multiple NF-κB-negative feedback loops. Cell
Res. 23:274–289. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chen Z, Wang S, Li HL, Luo H, Wu X, Lu J,
Wang HW, Chen Y, Chen D, Wu WT, et al: FOSL1 promotes
proneural-to-mesenchymal transition of glioblastoma stem cells via
UBC9/CYLD/NF-κB axis. Mol Ther. 30:2568–2583. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Song L, Liu L, Wu Z, Li Y, Ying Z, Lin C,
Wu J, Hu B, Cheng SY, Li M and Li J: TGF-β induces miR-182 to
sustain NF-κB activation in glioma subsets. J Clin Invest.
122:3563–3578. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Tauriello DVF, Haegebarth A, Kuper I,
Edelmann MJ, Henraat M, Canninga-van Dijk MR, Kessler BM, Clevers H
and Maurice MM: Loss of the tumor suppressor CYLD enhances
Wnt/β-catenin signaling through K63-linked ubiquitination of Dvl.
Mol Cell. 37:607–619. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Shirakawa Y, Ohta K, Miyake S, Kanemaru A,
Kuwano A, Yonemaru K, Uchino S, Yamaoka M, Ito Y, Ito N, et al:
Glioma cells acquire stem-like characters by extrinsic ribosome
stimuli. Cells. 10:29702021. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Hide T, Shibahara I, Inukai M, Shigeeda R,
Shirakawa Y, Jono H, Shinojima N, Mukasa A and Kumabe T: Ribosomal
proteins induce stem cell-like characteristics in glioma cells as
an ‘extra-ribosomal function.’. Brain Tumor Pathol. 39:51–56. 2022.
View Article : Google Scholar : PubMed/NCBI
|
